SKIN CANCERS IN IMMUNOCOMPROMISED PATIENTS: LESSONS FROM HEMATOLOGY AND TRANSPLANT MEDICINE

Abstract

Skin cancers in immunocompromised patients represent a significant clinical concern, particularly among individuals undergoing hematological treatments or organ transplantation. This study aimed to examine the epidemiology, risk factors, treatment outcomes, and biomarker profiles associated with skin malignancies in immunocompromised populations. A mixed-method approach was used, combining retrospective patient data analysis, laboratory reports, and clinical follow-ups. Results revealed that squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) were the most prevalent skin cancers in these patients, with SCC being notably more aggressive and recurrent in transplant recipients. Quantitative data showed a significantly higher incidence of skin cancer in patients exposed to long-term calcineurin inhibitors and azathioprine, while elevated levels of inflammatory biomarkers such as IL-6 and CRP were found to be predictive of tumor progression. The study also highlighted a correlation between duration of immunosuppression and cumulative UV exposure with increased tumor burden. Kaplan-Meier survival analysis indicated decreased overall survival in patients who developed skin malignancies post-transplant, compared to those without skin complications. Figures included multi-dimensional visualizations of cancer incidence by drug type, biomarker trends, and survival curves, while tables summarized clinical parameters, treatment regimens, recurrence rates, and patient-reported outcomes. The findings emphasize the need for personalized dermatologic surveillance, proactive patient education, and integrated care pathways involving dermatology, oncology, and transplant medicine to mitigate risks and improve prognosis in this vulnerable cohort.